AstraZeneca's breast cancer pill camizestrant (Etcamah) failed to meet its primary goal of improving progression-free survival in the late-stage SERENA-4 trial. The setback occurred on September 11, 2026, just one week after the drug received accelerated FDA approval for patients with ESR1 mutations. While the failure limits camizestrant's expansion into the larger first-line therapy market, analysts note the result was anticipated following a similar trial failure by competitor Roche in March 2026.
SERENA-4 trial failure
- ▪AstraZeneca's breast cancer drug camizestrant, sold as Etcamah, failed to meet its primary goal of improving progression-free survival in the late-stage SERENA-4 trial
- ▪The SERENA-4 trial tested camizestrant in combination with Pfizer's Ibrance against standard treatments in 1,371 previously untreated patients with ER-positive, HER2-negative advanced breast cancer
FDA accelerated approval timing
- ▪The FDA's accelerated approval of the Etcamah combination was specifically for treating breast cancer patients whose tumors have developed an ESR1 mutation
- ▪The U.S. Food and Drug Administration granted accelerated approval to the Etcamah combination on September 4, 2026, exactly one week before the SERENA-4 trial failure was announced
Stock price decline
- ▪U.S.-listed shares of AstraZeneca fell 3% in aftermarket trading on September 11, 2026, following the announcement of the trial failure
- ▪RBC Capital analyst Trung Huynh characterized the trial failure as a manageable setback that clears near-term uncertainty without changing the long-term investment case for camizestrant
Roche competitor trial failure
- ▪Barclays analyst James Gordon stated that the SERENA-4 trial failure was well anticipated by the market due to the prior failure of Roche's drug and cautious commentary from AstraZeneca
- ▪In March 2026, a similar oral breast cancer drug combination from Swiss drugmaker Roche failed to significantly slow disease progression in newly diagnosed patients
Peak sales projections
- ▪The SERENA-4 trial, had it been successful, could have opened up a much larger first-line therapy market for AstraZeneca's camizestrant
- ▪According to Jefferies, AstraZeneca projects peak annual sales potential of more than $5 billion for camizestrant, with the majority expected from the early breast cancer setting
Story comments
Loading comments…